Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 30.0% from a year ago
Cash & equivalents stood at $323.46M at the end of Q1 FY2026, down 30.0% from a year earlier and up 234.6% from the prior quarter. Over 3 fiscal years it compounded at +185.4% a year.
Context
- Cash & equivalents amounted to 58.4% of total assets at the end of Q1 FY2026, down 38.2 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -30.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 96.69M USD
- Year-over-year change
- -80.3%
- 3-year CAGR
- +185.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 96.69M | -80.3% |
| FY2024 | 2024-12-31 | 489.71M | +112.5% |
| FY2023 | 2023-12-31 | 230.44M | +5442.1% |
| FY2022 | 2022-12-31 | 4.16M | — |
Cash & Equivalents vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's Mar 2026 cash & equivalents of $323.46M is the highest of the 6 companies compared; the peer median is $66.52M.
- Its year-over-year change of -30.0% is the 4th highest of 6, against a peer median of -2.1%.
- Cash & equivalents amounts to 58.4% of total assets for BCAX, versus a peer median of 30.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
BCAXBicara Therapeutics Inc. Common Stock | Mar 2026 | $323.46M | -30.0% | +185.4% | 58.4% |
| Mar 2026 | $189.16M | +3269.4% | +64.5% | 95.0% | |
| Mar 2026 | $75.08M | -2.1% | -17.3% | 18.6% | |
| Mar 2026 | $66.52M | -54.3% | -19.3% | 30.5% | |
| Mar 2026 | $55.17M | +34.4% | -4.3% | 26.9% | |
| Mar 2026 | $54.53M | -39.0% | +23.0% | 92.6% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding BCAX) | $66.52M | -2.1% | -4.3% | 30.5% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.